Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

Oxamflatin

HDAC inhibitor
 
ALX-270-379-M001 1 mg 86.00 USD
 
ALX-270-379-M005 5 mg 314.00 USD
Do you need bulk/larger quantities?
 
Potent inhibitor of mammalian HDACs (histone deacetylases) (IC50=15.7nM). Acts as a ligand for the enzyme active site metal ion. Upregulates plasminogen activator inhibitor type 2 (PAI-2) expression with concomitant inhibition of urokinase (u-PA) gene and protein expression in HT-1080 and U-937 cells. Elevates the expression of extracellular matrix proteins fibronectin and gelsolin. Induces apoptosis in P-glyoprotein (Pgp) positive and Pgp negative multidrug resistant cells.

Product Specification

Alternative Name:(2E)-5-[3-(Phenylsulfonylamino)phenyl]pent-2-en-4-ynohydroxamic acid
 
Formula:C17H14N2O4S
 
MW:342.4
 
CAS:151720-43-3
 
Purity:≥95% (HPLC)
 
Appearance:Tan to yellow solid.
 
Solubility:Soluble in DMSO, methanol or acetonitrile.
 
Shipping:Shipped on Blue Ice
 
Long Term Storage:+4°C
 
Handling:Protect from light. Packaged under inert gas. After reconstitution, prepare aliquots and store at -20°C.
 
ALX-270-379 structure
Please mouse over
ALX-270-379 structure

Product Literature References

Inhibitors of histone deacetylases: correlation between isoform specificity and reactivation of HIV type 1 (HIV-1) from latently infected cells: K. Huber, et al.; J. Biol. Chem. 286, 22211 (2011), Abstract; Full Text
Novel mechanisms of apoptosis induced by histone deacetylase inhibitors: M.J. Peart, et al.; Cancer Res. 63, 4460 (2003), Abstract;
The novel anti-tumour agent oxamflatin differentially regulates urokinase and plasminogen activator inhibitor type 2 expression and inhibits urokinase-mediated proteolytic activity: A.E. Dear & R.L. Medcalf; Biochim. Biophys. Acta 1492, 15 (2000), Abstract;
Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase: Y.B. Kim, et al.; Oncogene 18, 2461 (1999), Abstract;
Oxamflatin: a novel compound which reverses malignant phenotype to normal one via induction of JunD: H. Sonoda, et al.; Oncogene 13, 143 (1996), Abstract;

Related Literature

Brochures
Stem Cells
Stem Cells
Download as PDF

Brochures
Epigenetics
Epigenetics
Download as PDF

All new literature pieces

Recommend this page

 
For Research Use Only. Not for use in diagnostic procedures.
Keep in touch

©2017 Enzo Life Sciences, Inc.,